Alterations of Mitochondrial DNA in Liver Diseases

Mitochondria in Liver Disease

Volumn , Issue , 2015, Pages 283-314

  Schon, Eric A ^a   Fromenty, Bernard ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85044357068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b19420-18     Document Type: Chapter

References (188)

1. Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, and Tirosh O. 2011. Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice. Lab Invest 91:1018–1028.
2. Alexandrova A, Kebis A, Mislanová C, and Kukan M. 2007. Copper impairs biliary epithelial cells and induces protein oxidation and oxidative DNA damage in the isolated perfused rat liver. Exp Toxicol Pathol 58:255–261.
3. Almeida MR, de Oliveira Lima E, da Silva VJ, Campos MG, Antunes LM, Salman AK, and Dias FL. 2008. Genotoxic studies in hypertensive and normotensive rats treated with amiodarone. Mutat Res 657:155–159.
4. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH et al. 2013. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58:777–787.
5. Area-Gomez E and Schon EA. 2014. Mitochondrial genetics and disease. J Child Neurol 29:1208–1215.
6. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, and Schon EA. 1991. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337:508–510.
7. Aubert J, Begriche K, Delannoy M, Morel I, Pajaud J, Ribault C, Lepage S et al. 2012. Differences in early acetaminophen hepatotoxicity between obese ob/ob and db/db mice. J Pharmacol Exp Ther 342:676–687.
8. Bäuerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, Schmutz G, Setzer B, Gatell JM, and Walker UA. 2005. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: Contributing effect of HIV infection? HIV Med 6:135–139.
9. Begriche K, Lettéron P, Abbey-Toby A, Vadrot N, Robin MA, Bado A, Pessayre D, and Fromenty B. 2008. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 294:E939–E951.
10. Begriche K, Massart J, Robin MA, Bonnet F, and Fromenty B. 2013. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 58:1497–1507.
11. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, and Fromenty B. 2011. Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J Hepatol 54:773–794.
12. Berson A, Renault S, Lettéron P, Robin MA, Fromenty B, Fau D, Le Bot MA et al. 1996. Uncoupling of rat and human mitochondria: A possible explanation for tacrine-induced liver dysfunction. Gastroenterology 110:1878–1890.
13. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, and Idle JR. 2013. Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology 58:229–238.
14. Bhala N, Jouness RI, and Bugianesi E. 2013. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 19:5169–5176.
15. Bianchi M, Rizza T, Verrigni D, Martinelli D, Tozzi G, Torraco A, Piemonte F et al. 2011. Novel large-range mitochondrial DNA deletions and fatal multisystemic disorder with prominent hepatopathy. Biochem Biophys Res Commun 415:300–304.
16. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, and Poupon R. 2004. Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol 28:720–759.
17. Bressler AM, Zimmer SM, Gilmore JL, and Somani J. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4:528–531.
18. Brown TA, Cecconi C, Tkachuk AN, Bustamante C, and Clayton DA. 2005. Replication of mitochondrial DNA occurs by strand displacement with alternative light-strand origins, not via a strand-coupled mechanism. Genes Dev 19:2466–2476.
19. Brown TT and Glesby MJ. 2011. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 8:11–21.
20. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M et al. 2005. Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330:932.
21. Cahill A, Cunningham CC, Adachi M, Ishii H, Bailey SM, Fromenty B, and Davies A. 2002. Effects of alcohol and oxidative stress on liver pathology: The role of the mitochondrion. Alcohol Clin Exp Res 26:907–915.
22. Cahill A, Stabley GJ, Wang X, and Hoek JB. 1999. Chronic ethanol consumption causes alterations in the structural integrity of mitochondrial DNA in aged rats. Hepatology 30:881–888.
23. Cahill A, Wang X, and Hoek JB. 1997. Increased oxidative damage to mitochondrial DNA following chronic ethanol consumption. Biochem Biophys Res Commun 235:286–290.
24. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, and Parker WD. 1999. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31:430–434.
25. Carabelli J, Burgueño AL, Rosselli MS, Gianotti TF, Lago NR, Pirola CJ, and Sookoian S. 2011. High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med 15:1329–1338.
26. Cardoso CM, Custodio JB, Almeida LM, and Moreno AJ. 2001. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 176:145–152.
27. Cardoso CM, Moreno AJ, Almeida LM, and Custodio JB. 2003. Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxytamoxifen. Toxicol In Vitro 17:663–670.
28. Carling PJ, Cree LM, and Chinnery PF. 2011. The implications of mitochondrial DNA copy number regulation during embryogenesis. Mitochondrion 11:686–692.
29. Carson J, Cerda J, Chae JH, Hirano M, and Maggiore P. 2007. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy 27:771–774.
30. Chen T, He J, Huang Y, and Zhao W. 2011. The generation of mitochondrial DNA large-scale deletions in human cells. J Hum Genet 56:689–694.
31. Christian BE and Spremulli LL. 2012. Mechanism of protein biosynthesis in mammalian mitochondria. Biochim Biophys Acta 1819:1035–1054.
32. Cover C, Mansouri A, Knight TR, Bajt ML, Lemasters JJ, Pessayre D, and Jaeschke H. 2005. Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J Pharmacol Exp Ther 315:879–887.
33. Damas J, Samuels DC, Carneiro J, Amorim A, and Pereira F. 2014. Mitochondrial DNA rearrangements in health and disease: A comprehensive study. Hum Mutat 35:1–14.
34. Davies SE, Williams R, and Portmann B. 1989. Hepatic morphology and histochemistry of Wilson’s disease presenting as fulminant hepatic failure: A study of 11 cases. Histopathology 15:385–394.
35. De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, and Van Vlierberghe H. 2010. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol 6:322–326.
36. Del Pozo JL, Fernández-Ros N, Sáez E, Herrero JI, Yuste JR, and Banales JM. 2014. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother 58: 4227–4229.
37. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Lettéron P et al. 2002. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 123: 1278–1290.
38. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, and Pessayre D. 1994. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions. Hepatology 19:948–961.
39. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ et al. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111–1117.
40. DiMauro S, Schon EA, Carelli V, and Hirano M. 2013. The clinical maze of mitochondrial neurology. Nat Rev Neurol 9:429–444.
41. El-Hattab AW, Li FY, Schmitt E, Zhang S, Craigen WJ, and Wong LJ. 2010. MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: New patients and novel mutations. Mol Genet Metab 99:300–308.
42. El-Hattab AW and Scaglia F. 2013. Mitochondrial DNA depletion syndromes: Review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics 10:186–198.
43. Fabbrini E, Sullivan S, and Klein S. 2010. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51:679–689.
44. Ferrari G, Lamantea E, Donati A, Filosto M, Briem E, Carrara F, Parini R, Simonati A, Santer R, and Zeviani M. 2005. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 128:723–731.
45. Fréneaux E, Labbe G, Letteron P, The Le Dinh, Degott C, Genève J, Larrey D, and Pessayre D. 1988. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8:1056–1062.
46. Fromenty B. 2013. Bridging the gap between old and new concepts in drug-induced liver injury. Clin Res Hepatol Gastroenterol 37:6–9.
47. Fromenty B, Carrozzo R, Shanske S, and Schon EA. 1997. High proportions of mtDNA duplications in patients with Kearns-Sayre syndrome occur in the heart. Am J Med Genet 71:443–452.
48. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, and Pessayre D. 1990. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377–1384.
49. Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, Rötig A, and Pessayre D. 1995. Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis. Gastroenterology 108:193–200.
50. Fromenty B and Pessayre D. 1995. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101–154.
51. Garazzino S, Krzysztofiak A, Esposito S, Castagnola E, Plebani A, Galli L, Cellini M et al. 2011. Use of linezolid in infants and children: A retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 66:2393–2397.
52. Garcia-Ruiz C and Fernandez-Checa JC. 2006. Mitochondrial glutathione: Hepatocellular survival-death switch. J Gastroenterol Hepatol 21(Suppl 3):S3–S6.
53. García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Grau M, Colina F, Muñoz-Yagüe T, and Solís-Herruzo JA. 2014. High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic steatohepatitis in mice. Dis Model Mech 7:1287–1296.
54. Gardner K, Hall PA, Chinnery PF, and Payne BA. 2013. HIV Treatment and associated mitochondrial pathology: Review of 25 years of in vitro, animal, and human studies. Toxicol Pathol 42:811–822.
55. Garrabou G, Soriano A, López S, Guallar JP, Giralt M, Villarroya F, Martínez JA et al. 2007. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 51:962–967.
56. Gosalakkal JA and Kamoji V. 2008. Reye syndrome and Reye-like syndrome. Pediatr Neurol 39:198–200.
57. Grabhorn E, Tsiakas K, Herden U, Fischer L, Freisinger P, Marquardt T, Ganschow R, Briem-Richter A, and Santer R. 2014. Long-term outcome after liver transplantation for deoxyguanosine kinase (DGUOK) deficiency. A single center experience and a review of the literature. Liver Transpl 20:464–472.
58. Gu M, Cooper JM, Butler P, Walker AP, Mistry PK, Dooley JS, and Schapira AH. 2000. Oxidative-phosphorylation defects in liver of patients with Wilson’s disease. Lancet 356:469–474.
59. Gürbay A, Gonthier B, Daveloose D, Favier A, and Hincal F. 2001. Microsomal metabolism of ciprofloxacin generates free radicals. Free Radic Biol Med 30:1118–1121.
60. Haas R, Stumpf DA, Parks JK, and Eguren L. 1981. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 31:1473–1476.
61. Helbling D, Buchaklian A, Wang J, Wong LJ, and Dimmock D. 2013. Reduced mitochondrial DNA content and heterozygous nuclear gene mutations in patients with acute liver failure. J Pediatr Gastroenterol Nutr 57:438–443.
62. Herraiz M, Beraza N, Solano A, Sangro B, Montoya J, Qian C, Prieto J, and Bustos M. 2003. Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 14:463–472.
63. Holt IJ and Reyes A. 2012. Human mitochondrial DNA replication. Cold Spring Harb Perspect Biol 4:a012971.
64. Honkoop P, Scholte HR, de Man RA, and Schalm SW. 1997. Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf 17:1–7.
65. Hsu CC, Lee HC, and Wei YH. 2013. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol 19:8880–8886.
66. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, and Xu G. 2013. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 73:4992–5002.
67. Igoudjil A, Abbey-Toby A, Begriche K, Grodet A, Chataigner K, Peytavin G, Maachi M et al. 2007. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther 12:389–400.
68. Igoudjil A, Begriche K, Pessayre D, and Fromenty B. 2006. Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Anti Infect Agents Med Chem 5: 273–292.
69. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin MA, and Fromenty B. 2008. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol In Vitro 22:887–898.
70. Ikeda S and Ozaki K. 1997. Action of mitochondrial endonuclease G on DNA damaged by L-ascorbic acid, peplomycin, and cis-diamminedichloroplatinum (II). Biochem Biophys Res Commun 235:291–294.
71. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, and Ylä-Herttuala S. 2004. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10:967–972.
72. Jaeschke H, McGill MR, and Ramachandran A. 2012. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 44:88–106.
73. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, and Johnson KA. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276:40847–40857.
74. Kakuda TN. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685–708.
75. Kamimura S, Gaal K, Britton RS, Bacon BR, Triadafilopoulos G, and Tsukamoto H. 1992. Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: Association of lipid peroxidation with liver fibrogenesis. Hepatology 16:448–453.
76. Kawahara H, Fukura M, Tsuchishima M, and Takase S. 2007. Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis. Alcohol Clin Exp Res 31(1 Suppl.):S54–S60.
77. Kazak L, Reyes A, and Holt IJ. 2012. Minimizing the damage: Repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 13:659–671.
78. Labarthe F, Dobbelaere D, Devisme L, De Muret A, Jardel C, Taanman JW, Gottrand F, and Lombès A. 2005. Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 43:333–341.
79. Labbe G, Fromenty B, Freneaux E, Morzelle V, Letteron P, Berson A, and Pessayre D. 1991. Effects of various tetracycline derivatives on in vitro and in vivo beta-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol 41:638–641.
80. Larosche I, Choumar A, Fromenty B, Lettéron P, Abbey-Toby A, Van Remmen H, Epstein CJ et al. 2009. Prolonged ethanol administration depletes mitochondrial DNA in MnSOD-overexpressing transgenic mice, but not in their wild type littermates. Toxicol Appl Pharmacol 234:326–338.
81. Larosche I, Lettéron P, Berson A, Fromenty B, Huang TT, Moreau R, Pessayre D, and Mansouri A. 2010. Hepatic mitochondrial DNA depletion after an alcohol binge in mice: Probable role of peroxynitrite and modulation by manganese superoxide dismutase. J Pharmacol Exp Ther 332:886–897.
82. Larosche I, Lettéron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, and Mansouri A. 2007. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 321:526–535.
83. Larson AM. 2007. Acetaminophen hepatotoxicity. Clin Liver Dis 11:525–548.
84. Lawrence JW, Claire DC, Weissig V, and Rowe TC. 1996. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 50:1178–1188.
85. Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, and Rowe TC. 1993. 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell Biochem 51:165–174.
86. Lee HC, Li SH, Lin JC, Wu CC, Yeh DC, and Wei YH. 2004. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 547:71–78.
87. Lee HC, Pang CY, Hsu HS, and Wei YH. 1994. Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human ageing. Biochim Biophys Acta 1226:37–43.
88. Lee HF, Tsai CR, Chi CS, Lee HJ, and Chen CC. 2009. Leigh syndrome: Clinical and neuroimaging follow-up. Pediatr Neurol 40:88–93.
89. Lee WS and Sokol RJ. 2007. Mitochondrial hepatopathies: Advances in genetics and pathogenesis. Hepatology 45:1555–1565.
90. Lettéron P, Sutton A, Mansouri A, Fromenty B, and Pessayre D. 2003. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38:133–140.
91. Leung TM and Nieto N. 2013. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 58:395–398.
92. Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, de Courten-Myers G et al. 1997. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77–87.
93. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, Watanabe KA, and Perrino FW. 1996. Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 93:3592–3597.
94. Lieber CS, Leo MA, Wang X, and Decarli LM. 2008. Effect of chronic alcohol consumption on Hepatic SIRT1 and PGC-1α in rats. Biochem Biophys Res Commun 370:44–48.
95. Liu VW, Zhang C, Linnane AW, and Nagley P. 1997. Quantitative allele-specific PCR: demonstration of age-associated accumulation in human tissues of the A → G mutation at nucleotide 3243 in mitochondrial DNA. Hum Mutat 9:265–271.
96. Lund KC, Peterson LL, and Wallace KB. 2007. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51:2531–2539.
97. Lutz RE, Dimmock D, Schmitt ES, Zhang Q, Tang LY, Reyes C, Truemper E et al. 2009. De novo mutations in POLG presenting with acute liver failure or encephalopathy. J Pediatr Gastroenterol Nutr 49:126–129.
98. Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, and Iancu TC. 2001. The hepatic mitochondrial DNA depletion syndrome: Ultrastructural changes in liver biopsies. Hepatology 34:776–784.
99. Manfredi G, Vu T, Bonilla E, Schon EA, DiMauro S, Arnaudo E, Zhang L, Rowland LP, and Hirano M. 1997. Association of myopathy with large-scale mitochondrial DNA duplications and deletions: Which is pathogenic? Ann Neurol 42:180–188.
100. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, and Fromenty B. 2001. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: Protective effects of antioxidants. J Pharmacol Exp Ther 298:737–743.
101. Mansouri A, Fromenty B, Berson A, Robin MA, Grimbert S, Beaugrand M, Erlinger S, and Pessayre D. 1997b. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. J Hepatol 27:96–102.
102. Mansouri A, Gaou I, De Kerguenec C, Amsellem S, Haouzi D, Berson A, Moreau A et al. 1999. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 117:181–190.
103. Mansouri A, Gaou I, Fromenty B, Berson A, Lettéron P, Degott C, Erlinger S, and Pessayre D. 1997a. Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease. Gastroenterology 113:599–605.
104. Mansouri A, Haouzi D, Descatoire V, Demeilliers C, Sutton A, Vadrot N, Fromenty B, Feldmann G, Pessayre D, and Berson A. 2003. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 38:715–725.
105. Mansouri A, Tarhuni A, Larosche I, Reyl-Desmars F, Demeilliers C, Degoul F, Nahon P et al. 2010. MnSOD overexpression prevents liver mitochondrial DNA depletion after an alcohol binge but worsens this effect after prolonged alcohol consumption in mice. Dig Dis 28:756–775.
106. Mantena SK, King AL, Andringa KK, Landar A, Darley-Usmar V, and Bailey SM. 2007. Novel interactions of mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver disease. World J Gastroenterol 13:4967–4973.
107. Martin W. 2010. Evolutionary origins of metabolic compartmentalization in eukaryotes. Philos Trans R Soc Lond B, Biol Sci 365:847–855.
108. Massart J, Begriche K, Buron N, Porceddu M, Borgne-Sanchez A, and Fromenty B. 2013. Drug-induced inhibition of mitochondrial fatty acid oxidation and steatosis. Curr Pathobiol Rep 1:147–157.
109. Matthews LT, Giddy J, Ghebremichael M, Hampton J, Guarino AJ, Ewusi A, Carver E et al. 2011. A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. PLoS One 64:e18736.
110. McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, and Jaeschke H. 2012. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest 122:1574–1583.
111. McGill MR, Staggs VS, Sharpe MR, Lee WM, and Jaeschke H. 2014. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 60:1336–1345.
112. McGlynn KA and London WT. 2011. The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis 15:223–243.
113. McKee EE, Ferguson M, Bentley AT, and Marks TA. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50:2042–2049.
114. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, and Luciano C. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099–1105.
115. McShane MA, Hammans SR, Sweeney M, Holt IJ, Beattie TJ, Brett EM, and Harding AE. 1991. Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am J Hum Genet 48:39–42.
116. Mitchell P and Moyle J. 1967. Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213:137–139.
117. Morris AA, Lamont PJ, and Clayton PT. 1997. Pearson’s syndrome without marrow involvement. Arch Dis Child 77:56–57.
118. Morris EM, Meers GM, Booth FW, Fritsche KL, Hardin CD, Thyfault JP, and Ibdah JA. 2012. PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. Am J Physiol Gastrointest Liver Physiol 303:G979–G992.
119. Muraki K, Sakura N, Ueda H, Kihara H, and Goto Y. 2001. Clinical implications of duplicated mtDNA in Pearson syndrome. Am J Med Genet 98:205–209.
120. Murayama K and Ohtake A. 2009. Children’s toxicology from bench to bed. Liver Injury (4): Mitochondrial respiratory chain disorder and liver disease in children. J Toxicol Sci 34: SP237–SP243.
121. Nagasaka H, Inoue I, Inui A, Komatsu H, Sogo T, Murayama K, Murakami T et al. 2006. Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: Hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. Pediatr Res 60:472–477.
122. Nagiec EE, Wu L, Swaney SM, Chosay JG, Ross DE, Brieland JK, and Leach KL. 2005. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother 49:3896–3902.
123. Nair J, Strand S, Frank N, Knauft J, Wesch H, Galle PR, and Bartsch H. 2005. Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: Enhanced DNA damage by dietary curcumin upon copper accumulation. Carcinogenesis 26:1307–1315.
124. Nishikawa M, Nishiguchi S, Kioka K, Tamori A, and Inoue M. 2005. Interferon reduces somatic mutation of mitochondrial DNA in liver tissues from chronic viral hepatitis patients. J Viral Hepat 12:494–498.
125. Nishikawa M, Nishiguchi S, Shiomi S, Tamori A, Koh N, Takeda T, Kubo S et al. 2001. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 61:1843–1845.
126. Nomoto K, Tsuneyama K, Takahashi H, Murai Y, and Takano Y. 2008. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 16:71–75.
127. Nunez M. 2010. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52:1143–1155.
128. Obara-Moszynska M, Maceluch J, Bobkowski W, Baszko A, Jaremba O, Krawczynski MR, and Niedziela M. 2013. A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: A late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment. BMC Pediatr 13:27.
129. Ojala D, Montoya J, and Attardi G. 1981. tRNA punctuation model of RNA processing in human mitochondria. Nature 290:470–474.
130. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, and Hayashi PH. 2011. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9:517–523.
131. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, Colina F, Arenas J, and Solis-Herruzo JA. 2003. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38:999–1007.
132. Pirola CJ, Gianotti TF, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO, and Sookoian S. 2013. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 62:1356–1363.
133. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, and Borgne-Sanchez A. 2012. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 129:332–345.
134. Quinonez SC, Leber SM, Martin DM, Thoene JG, and Bedoyan JK. 2013. Leigh syndrome in a girl with a novel DLD mutation causing E3 deficiency. Pediatr Neurol 48:67–72.
135. Ramachandran R and Kakar S. 2009. Histological patterns in drug-induced liver disease. J Clin Pathol 62:481–492.
136. Richter C. 1995. Oxidative damage to mitochondrial DNA and its relationship to ageing. Int J Biochem Cell Biol 27:647–653.
137. Roberts EA and Schilsky ML. 2008. Diagnosis and treatment of Wilson disease: An update. Hepatology 47:2089–2111.
138. Robertson DG, Braden TK, Urda ER, Lalwani ND, and de la Iglesia FA. 1998. Elucidation of mitochondrial effects by tetrahydroaminoacridine (tacrine) in rat, dog, monkey and human hepatic parenchymal cells. Arch Toxicol 72:362–371.
139. Robin MA, Sauvage I, Grandperret T, Descatoire V, Pessayre D, and Fromenty B. 2005. Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett 579:6895–6902.
140. Rötig A, Bourgeron T, Chretien D, Rustin P, and Munnich A. 1995. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 4:1327–1330.
141. Rötig A, Cormier V, Blanche S, Bonnefont JP, Ledeist F, Romero N, Schmitz J et al. 1990. Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest 86:1601–1608.
142. Sakr SA, Zoil Mel-S, and El-Shafey SS. 2013. Ameliorative effect of grapefruit juice on amiodarone-induced cytogenetic and testicular damage in albino rats. Asian Pac J Trop Biomed 3:573–579.
143. Sarzi E, Bourdon A, Chrétien D, Zarhrate M, Corcos J, Slama A, Cormier-Daire V et al. 2007. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 150:531–534.
144. Sauer SW, Merle U, Opp S, Haas D, Hoffmann GF, Stremmel W, and Okun JG. 2011. Severe dysfunction of respiratory chain and cholesterol metabolism in Atp7b(−/−) mice as a model for Wilson disease. Biochim Biophys Acta 1812:1607–1615.
145. Schon EA, DiMauro S, and Hirano M. 2012. Human mitochondrial DNA: Roles of inherited and somatic mutations. Nat Rev Genet 13:878–890.
146. Semino-Mora C, Leon-Monzon M, and Dalakas MC. 1997. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab Invest 76:487–495.
147. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, and Miles BJ. 2000. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163:1747–1750.
148. Shea BF, Hoffman S, Sesin GP, and Hammer SM. 1987. Ganciclovir hepatotoxicity. Pharmacotherapy 7:223–236.
149. Shieh JT, Berquist WE, Zhang Q, Chou PC, Wong LJ, and Enns GM. 2009. Novel deoxyguanosine kinase gene mutations and viral infection predispose apparently healthy children to fulminant liver failure. J Pediatr Gastroenterol Nutr 49:130–132.
150. Shoubridge EA and Wai T. 2007. Mitochondrial DNA and the mammalian oocyte. Curr Top Dev Biol 77:87–111.
151. Simonetti S, Chen X, DiMauro S, and Schon EA. 1992. Accumulation of deletions in human mitochondrial DNA during normal aging: Analysis by quantitative PCR. Biochim Biophys Acta 1180:113–122.
152. Sokol RJ, Twedt D, McKim JM Jr, Devereaux MW, Karrer FM, Kam I, von Steigman G, Narkewicz MR, Bacon BR, and Britton RS. 1994. Oxidant injury to hepatic mitochondria in patients with Wilson’s disease and Bedlington terriers with copper toxicosis. Gastroenterology 107:1788–1798.
153. Soriano A, Miró O, and Mensa J. 2005. Mitochondrial toxicity associated with linezolid. N Engl J Med 353:2305–2306.
154. Spinazzola A, Santer R, Akman OH, Tsiakas K, Schaefer H, Ding X, Karadimas CL et al. 2008. Hepatocerebral form of mitochondrial DNA depletion syndrome: Novel MPV17 mutations. Arch Neurol 65:1108–1113.
155. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A et al. 1998. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092.
156. Sternlieb I and Feldmann G. 1976. Effects of anticopper therapy on hepatocellular mitochondria in patients with Wilson’s disease: An ultrastructural and stereological study. Gastroenterology 71:457–461.
157. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, and Chinnery PF. 2010. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52:1791–1796.
158. Sun W, Xing B, Sun Y, Du X, Lu M, Hao C, Lu Z et al. 2007. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: Novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 6:1798–1808.
159. Tamori A, Nishiguchi S, Nishikawa M, Kubo S, Koh N, Hirohashi K, Shiomi S, and Inoue M. 2004. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol 39:1063–1068.
160. Tang Y, Schon EA, Wilichowski E, Vazquez-Memije ME, Davidson E, and King MP. 2000. Rearrangements of human mitochondrial DNA (mtDNA): New insights into the regulation of mtDNA copy number and gene expression. Mol Biol Cell 11:1471–1485.
161. Temperley R, Richter R, Dennerlein S, Lightowlers RN, and Chrzanowska-Lightowlers ZM. 2010. Hungry codons promote frameshifting in human mitochondrial ribosomes. Science 327:301.
162. Thust R, Tomicic M, Klöcking R, Voutilainen N, Wutzler P, and Kaina B. 2000. Comparison of the genotoxic and apoptosis–inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches. Cancer Gene Ther 7:107–117.
163. Toyokuni S and Sagripanti JL. 1996. Association between 8-hydroxy-2′-deoxyguanosine formation and DNA strand breaks mediated by copper and iron. Free Radic Biol Med 20:859–864.
164. Tuquet C, Dupont J, Mesneau A, and Roussaux J. 2000. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol Toxicol 16:207–219.
165. Uusimaa J, Evans J, Smith C, Butterworth A, Craig K, Ashley N, Liao C et al. 2014. Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. Eur J Hum Genet 22:184–191.
166. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, and Martínez JA. 2012. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity 20:1974–1983.
167. van der Eb MM, Geutskens SB, van Kuilenburg AB, van Lenthe H, van Dierendonck JH, Kuppen PJ, van Ormondt H et al. 2003. Ganciclovir nucleotides accumulate in mitochondria of rat liver cells expressing the herpes simplex virus thymidine kinase gene. J Gene Med 5:1018–1027.
168. Velez JC and Janech MG. 2010. A case of lactic acidosis induced by linezolid. Nat Rev Nephrol 6:236–242.
169. Vella S, Schwartländer B, Sow SP, Eholie SP, and Murphy RL. 2012. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26:1231–1241.
170. Vidyashankar S and Patki PS. 2010. Liv.52 attenuate copper induced toxicity by inhibiting glutathione depletion and increased antioxidant enzyme activity in HepG2 cells. Food Chem Toxicol 48:1863–1868.
171. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, and Mallolas J. 2004. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 39:311–317.
172. Wang Y, Lin Z, Liu Z, Harris S, Kelly R, Zhang J, Ge W, Chen M, Borlak J, and Tong W. 2013. A unifying ontology to integrate histological and clinical observations for drug-induced liver injury. Am J Pathol 182:1180–1187.
173. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, and Lewis KW. 1994. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 271:992–998.
174. Weyers AI, Ugnia LI, García Ovando H, and Gorla NB. 2002. Ciprofloxacin increases hepatic and renal lipid hydroperoxides levels in mice. Biocell 26:225–228.
175. Wheelhouse NM, Lai PB, Wigmore SJ, Ross JA, and Harrison DJ. 2005. Mitochondrial D-loop mutations and deletion profiles of cancerous and noncancerous liver tissue in hepatitis B virus-infected liver. Br J Cancer 92:1268–1272.
176. Wirth T, Parker N, and Ylä-Herttuala S. 2013. History of gene therapy. Gene 525:162–169.
177. Xiao J, Han N, Yang D, and Zhao H. 2013. Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors. Virol J 10:261.
178. Yamada S, Nomoto S, Fujii T, Kaneko T, Takeda S, Inoue S, Kanazumi N, and Nakao A. 2006. Correlation between copy number of mitochondrial DNA and clinico-pathologic parameters of hepatocellular carcinoma. Eur J Surg Oncol 32:303–307.
179. Ye Y, Huang A, Huang C, Liu J, Wang B, Lin K, Chen Q et al. 2013. Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients. Proteomics Clin Appl 7:403–415.
180. Yin H, Hu M, Zhang R, Shen Z, Flatow L, and You M. 2012. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 287:9817–9826.
181. Yin PH, Lee HC, Chau GY, Wu YT, Li SH, Lui WY, Wei YH, Liu TY, and Chi CW. 2004. Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer 90:2390–2396.
182. Yin PH, Wu CC, Lin JC, Chi CW, Wei YH, and Lee HC. 2010. Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Mitochondrion 10:174–182.
183. Yu HY, Wang BL, Zhao J, Yao XM, Gu Y, and Li Y. 2009. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology 261:112–118.
184. Yuzefovych LV, LeDoux SP, Wilson GL, and Rachek LI. 2013. Mitochondrial DNA damage via augmented oxidative stress regulates endoplasmic reticulum stress and autophagy: Crosstalk, links and signaling. PLoS One 8:e83349.
185. Zenger K, Chen X, Decker M, and Kraus B. 2013. In-vitro stability and metabolism of a tacrine-silibinin codrug. J Pharm Pharmacol 65:1765–1772.
186. Zhang X, Tachibana S, Wang H, Hisada M, Williams GM, Gao B, and Sun Z. 2010. Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology 52:2137–2147.
187. Zischka H and Lichtmannegger J. 2014. Pathological mitochondrial copper overload in livers of Wilson’s disease patients and related animal models. Ann N Y Acad Sci 1315:6–15.
188. Zischka H, Lichtmannegger J, Schmitt S, Jägemann N, Schulz S, Wartini D, Jennen L et al. 2011. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 121:1508–1518.